Please login to the form below

Not currently logged in
Email:
Password:

Bayer appoints president of Americas pharma business

Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America

Bayer Dr Carsten BrunnBayer has appointed Dr Carsten Brunn as the president of its pharmaceuticals business in the Americas, overseeing the company's operations in the US, Canada and Central and Latin America.

Dr Brunn first joined Bayer in 2011 as global head of primary care, based in Beijing, China, and has subsequently served as head of Bayer's pharmaceuticals commercial operations in Japan since 2013.

Prior to this, Dr Brunn was vice president of pharma, Asia-Pacific at Bausch & Lomb and served as global head of marketing at Basilea Pharmaceutica International, based in Basel, Switzerland.

He also brings branding and sales leadership experience from Novartis and Eli Lilly, and recently served as chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan.

Dieter Weinand, president of Bayer's pharmaceutical division, said: “Carsten is a strategic and highly respected leader in the pharmaceutical industry and I'm delighted to have him lead the company's largest pharmaceutical business worldwide.

“Carsten's global perspective and proven track record of successful operational executive at the local level will be a critical asset to us as we continue to build on our current momentum in the US and across the Americas region.”

26th January 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...